The CD37-targeted antibody-drug conjugate IMGN529 is highly active against human CLL and in a novel CD37 transgenic murine leukemia model

Therapeutic regimens for chronic lymphocytic leukemia (CLL) have increasingly utilized monoclonal antibodies since the chimeric anti-CD20 antibody rituximab was introduced. Despite improved clinical outcomes, current CLL therapies are not curative. Therefore, antibodies with greater efficacy and nov...

Descripción completa

Detalles Bibliográficos
Autores principales: Beckwith, Kyle A., Frissora, Frank W., Stefanovski, Matthew R., Towns, William H., Cheney, Carolyn, Mo, Xiaokui, Deckert, Jutta, Croce, Carlo M., Flynn, Joseph M., Andritsos, Leslie A., Jones, Jeffrey A., Maddocks, Kami J., Lozanski, Gerard, Byrd, John C., Muthusamy, Natarajan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2014
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4090271/
https://www.ncbi.nlm.nih.gov/pubmed/24445867
http://dx.doi.org/10.1038/leu.2014.32

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4090271/
https://www.ncbi.nlm.nih.gov/pubmed/24445867
http://dx.doi.org/10.1038/leu.2014.32

Ejemplares similares